Columbia University is pleased to announce the Columbia - SDP Oncology Research Alliance. This collaboration stimulates research and development in the field of oncology through collaborative, Columbia investigator initiated projects.
Questions? Please read FAQs below and/or reach out to the Columbia Alliance Manager, Sam Galindo at [email protected]
Sumitomo Dainippon Pharma Oncology, Inc., is a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. As a global oncology organization with teams in the U.S. and Japan, SDP Oncology is relentlessly committed to advancing purposeful science by transforming new discoveries into meaningful treatments for patients with cancer. The company's robust and diverse pipeline of preclinical and advanced-stage assets spans multiple areas, including oncogenic pathways, survival mechanisms and novel protein interactions, which aim to address unmet clinical needs in oncology.